OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
DNA Encoded Libraries (DELs) have become an important and efficient approach for identifying novel chemical entities targeting a range of biomolecular architectures.
Barry Morgan led the development of the DEL platform at Praecis Pharmaceuticals, Boston, joining GSK to lead its continued investment in DEL screening after GSK bought Praecis in 2007. Since that time GSK has gone on to publish several novel chemical entities, now in late phase clinical development. What started as a theory from Sydney Brenner & Richard Lerner has truly come of age as a powerful drug-discovery approach.
Barry is now CSO at HitGen, who continue to build a strong DEL platform based in Chengdu, China.
